DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Greatest International Antiinfective Trial With Avelox

Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bronchitis, Chronic; Bronchial Diseases

Intervention: Moxifloxacin (Avelox, BAY12-8039) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer

Summary

The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.

Clinical Details

Official title: GIANT - Greatest International Antiinfective Trial With Avelox«

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Evaluation of impact of AECB on the patient and the community as well as effect and safety of a treatment with moxifloxacin tablets in daily life clinical practice

Secondary outcome:

Course of symptom relief

Speed of return to normal daily life activities

Adverse events collection

Evaluation of frequency of new exacerbations

Progression of chronic respiratory disease

Eligibility

Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Outpatients with diagnosis of AECB and decision taken by the investigator to

prescribe moxifloxacin Exclusion Criteria:

- Exclusion criteria must be read in conjunction with the local product information

Locations and Contacts

Many Locations, Austria

Many Locations, Brazil

Many Locations, China

Many Locations, Colombia

Many Locations, Croatia

Many Locations, Egypt

Many Locations, El Salvador

Many Locations, Germany

Many Locations, Hong Kong

Many Locations, Hungary

Many Locations, Indonesia

Many Locations, Korea, Republic of

Many Locations, Malaysia

Many Locations, Mexico

Many Locations, Morocco

Many Locations, Netherlands

Many Locations, Pakistan

Many Locations, Philippines

Many Locations, Poland

Many Locations, Singapore

Many Locations, Slovenia

Many Locations, Switzerland

Many Locations, Taiwan

Many Locations, Turkey

Additional Information

Click here and search for drug information provided by the FDA.

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Starting date: February 2004
Last updated: November 16, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017